請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/89516
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 方啓泰 | zh_TW |
dc.contributor.advisor | Chi-Tai Fang | en |
dc.contributor.author | 潘秉儀 | zh_TW |
dc.contributor.author | Bing-Yi Pan | en |
dc.date.accessioned | 2023-09-08T16:07:50Z | - |
dc.date.available | 2023-11-09 | - |
dc.date.copyright | 2023-09-08 | - |
dc.date.issued | 2023 | - |
dc.date.submitted | 2023-08-05 | - |
dc.identifier.citation | WHO Coronavirus (COVID-19) Dashboard. https://www.who.int/ (accessed March 31 2023).
Guo K, Ni P, Chang S, Jin Y, Duan G, Zhang R. Effectiveness of mRNA vaccine against Omicron-related infections in the real world: A systematic review and meta-analysis. American journal of infection control 2023. Higdon MM, Baidya A, Walter KK, et al. Duration of effectiveness of vaccination against COVID-19 caused by the omicron variant. The Lancet Infectious Diseases 2022; 22(8): 1114-6. Meggiolaro A, Sane Schepisi M, Farina S, et al. Effectiveness of vaccination against SARS-CoV-2 Omicron variant infection, symptomatic disease, and hospitalization: a systematic review and meta-analysis. Expert Review of Vaccines 2022; 21(12): 1831-41. Mohammed H, Pham-Tran DD, Yeoh ZYM, et al. A Systematic Review and Meta-Analysis on the Real-World Effectiveness of COVID-19 Vaccines against Infection, Symptomatic and Severe COVID-19 Disease Caused by the Omicron Variant (B.1.1.529). Vaccines 2023; 11(2): 224. Pratama NR, Wafa IA, Budi DS, et al. Effectiveness of COVID-19 Vaccines against SARS-CoV-2 Omicron Variant (B.1.1.529): A Systematic Review with Meta-Analysis and Meta-Regression. Vaccines 2022; 10(12): 2180. Wu N, Joyal-Desmarais K, Ribeiro PAB, et al. Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022. The Lancet Respiratory Medicine 2023. Zhu Y, Liu S, Zhang D. Effectiveness of COVID-19 Vaccine Booster Shot Compared with Non-Booster: A Meta-Analysis. Vaccines 2022; 10(9): 1396. Zou Y, Huang D, Jiang Q, Guo Y, Chen C. The Vaccine Efficacy Against the SARS-CoV-2 Omicron: A Systemic Review and Meta-Analysis. Front Public Health 2022; 10: 940956. Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016: i4919. Schunemann H. GRADE handbook for grading quality of evidence and strength of recommendation. Version 3.2. http://wwwcc-imsnet/gradepro 2008. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011; 64(4): 383-94. Grading quality of evidence and strength of recommendations. BMJ 2004; 328(7454): 1490. Wu M, Wall EC, Carr EJ, et al. Three-dose vaccination elicits neutralising antibodies against omicron. The Lancet 2022; 399(10326): 715-7. Chen Z, Zhang Y, Wang M, et al. Humoral and Cellular Immune Responses of COVID-19 vaccines against SARS-Cov-2 Omicron variant: a systemic review. International Journal of Biological Sciences 2022; 18(12): 4629-41. Cheng H, Peng Z, Si S, et al. Neutralization Activity against SARS-CoV-2 Variants after Booster Vaccination in Populations without COVID-19: A Meta-Analysis. Vaccines 2022; 10(7): 1101. Gruell H, Vanshylla K, Tober-Lau P, et al. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. Nature Medicine 2022; 28(3): 477-80. Cromer D, Steain M, Reynaldi A, et al. Predicting vaccine effectiveness against severe COVID-19 over time and against variants: a meta-analysis. Nature Communications 2023; 14(1). Favresse J, Gillot C, Bayart JL, et al. Vaccine‐induced binding and neutralizing antibodies against Omicron 6 months after a homologous BNT162b2 booster. Journal of Medical Virology 2023; 95(1). Cromer D, Steain M, Reynaldi A, et al. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. The Lancet Microbe 2022; 3(1): e52-e61. Menegale F, Manica M, Zardini A, et al. Evaluation of Waning of SARS-CoV-2 Vaccine–Induced Immunity. JAMA Network Open 2023; 6(5): e2310650. Jacobsen H, Katzmarzyk M, Higdon MM, et al. Post-Vaccination Neutralization Responses to Omicron Sub-Variants. Vaccines 2022; 10(10): 1757. Bobrovitz N, Ware H, Ma X, et al. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. The Lancet Infectious Diseases 2023. Accorsi EK, Britton A, Fleming-Dutra KE, et al. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. Jama 2022; 327(7): 639-51. Andersson NW, Thiesson EM, Baum U, et al. Comparative effectiveness of heterologous booster schedules with AZD1222, BNT162b2, or mRNA-1273 vaccines against COVID-19 during omicron predominance in the Nordic countries. 2022. Butt AA, Talisa VB, Shaikh OS, Omer SB, Mayr FB. Relative Vaccine Effectiveness of a SARS-CoV-2 mRNA Vaccine Booster Dose Against the Omicron Variant. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2022. Cerqueira-Silva T, de Araujo Oliveira V, Paixão ES, et al. Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil. Nature Communications 2022; 13(1). Cerqueira-Silva T, Shah SA, Robertson C, et al. Effectiveness of mRNA boosters after homologous primary series with BNT162b2 or ChAdOx1 against symptomatic infection and severe COVID-19 in Brazil and Scotland: A test-negative design case–control study. PLoS Medicine 2023; 20(1). Chemaitelly H, Ayoub HH, Tang P, et al. Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study. The Lancet Infectious diseases 2023. Florea A, Sy LS, Qian L, et al. Effectiveness of Messenger RNA-1273 Vaccine Booster Against Coronavirus Disease 2019 in Immunocompetent Adults. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2023; 76(2): 252-62. González S, Olszevicki S, Gaiano A, et al. Protection of homologous and heterologous boosters after primary schemes of rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV during the Omicron outbreak in adults of 50 years and older in Argentina: a test-negative case-control study. 2022. Ioannou GN, Bohnert ASB, O'Hare AM, et al. Effectiveness of mRNA COVID-19 Vaccine Boosters Against Infection, Hospitalization, and Death: A Target Trial Emulation in the Omicron (B.1.1.529) Variant Era. Annals of Internal Medicine 2022; 175(12): 1693-707. Kim SR, Kang HJ, Jeong HR, et al. Relative Effectiveness of COVID-19 Vaccination in Healthcare Workers: 3-Dose Versus 2-Dose Vaccination. Journal of Korean medical science 2022; 37(35): e267. Korves C, Izurieta HS, Smith J, et al. Relative effectiveness of booster vs. 2-dose mRNA Covid-19 vaccination in the Veterans Health Administration: Self-controlled risk interval analysis. Vaccine 2022; 40(33): 4742-7. Laake I, Skodvin SN, Blix K, et al. Effectiveness of mRNA booster vaccination against mild, moderate, and severe COVID-19 caused by the Omicron variant in a large, population-based, Norwegian cohort. The Journal of infectious diseases 2022. Lai FTT, Yan VKC, Ye X, et al. Booster vaccination with inactivated whole-virus or mRNA vaccines and COVID-19–related deaths among people with multimorbidity: a cohort study. CMAJ Canadian Medical Association Journal 2023; 195(4): E143-E52. Lind ML, Robertson AJ, Silva J, et al. Association between primary or booster COVID-19 mRNA vaccination and Omicron lineage BA.1 SARS-CoV-2 infection in people with a prior SARS-CoV-2 infection: A testnegative case-control analysis. PLoS Medicine 2022; 19(12). Link-Gelles R, Levy ME, Natarajan K, et al. Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status during Omicron BA.4 and BA.5 Sublineage Periods. JAMA Network Open 2023; 6(3): E232598. Liu B, Gidding H, Stepien S, Cretikos M, Macartney K. Relative effectiveness of COVID-19 vaccination with 3 compared to 2 doses against SARS-CoV-2 B.1.1.529 (Omicron) among an Australian population with low prior rates of SARS-CoV-2 infection. Vaccine 2022; 40(43): 6288-94. Maeda H, Saito N, Igarashi A, et al. Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 Omicron BA.1 and BA.2 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS). Expert Review of Vaccines 2023; 22(1): 288-98. Martínez-Baz I, Trobajo-Sanmartín C, Miqueleiz A, et al. Risk reduction of hospitalisation and severe disease in vaccinated COVID-19 cases during the SARS-CoV-2 variant Omicron BA.1-predominant period, Navarre, Spain, January to March 2022. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 2023; 28(5). McConeghy KW, Bardenheier B, Huang AW, et al. Infections, Hospitalizations, and Deaths among US Nursing Home Residents with vs Without a SARS-CoV-2 Vaccine Booster. JAMA Network Open 2022; 5(12): E2245417. Miyauchi S, Hiyama T, Nakano Y, et al. Real-World Effectiveness of a Booster Dose of the COVID-19 Vaccines among Japanese University Students. Vaccines 2022; 10(8). Monge S, Rojas-Benedicto A, Olmedo C, et al. Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 omicron (B.1.1.529) variant in Spain: a nationwide cohort study. The Lancet Infectious Diseases 2022; 22(9): 1313-20. Ng OT, Marimuthu K, Lim N, et al. Analysis of COVID-19 Incidence and Severity among Adults Vaccinated with 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines with and Without Boosters in Singapore. JAMA Network Open 2022; 5(8): E2228900. Norddahl GL, Melsted P, Gunnarsdottir K, et al. Effect of booster vaccination against Delta and Omicron SARS-CoV-2 variants in Iceland. Nature Communications 2022; 13(1). Patalon T, Saciuk Y, Peretz A, et al. Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine. Nature Communications 2022; 13(1). Petrie JG, King JP, McClure DL, et al. Effectiveness of first and second COVID-19 mRNA vaccine monovalent booster doses during a period of circulation of Omicron variant sublineages: December 2021-July 2022. Influenza and other respiratory viruses 2023; 17(3): e13104. Ranzani OT, Hitchings MDT, de Melo RL, et al. Effectiveness of an Inactivated Covid-19 Vaccine with Homologous and Heterologous Boosters against the Omicron (B.1.1.529) Variant. 2022. Richterman A, Behrman A, Brennan PJ, O’DONNELL JA, Snider CK, Chaiyachati KH. Durability of SARS-CoV-2 mRNA Booster Vaccine Protection Against Omicron Among Health Care Workers with a Vaccine Mandate. Clinical Infectious Diseases. Robilotti EV, Whiting K, Lucca A, et al. Effectiveness of MRNA booster vaccine among healthcare workers in New York City during the Omicron surge, December 2021 to January 2022. Clinical Microbiology and Infection 2022; 28(12): 1624-8. Saito Y, Yamamoto K, Takita M, Kami M, Tsubokura M, Shibuya K. Effectiveness of the Booster of SARS-CoV-2 Vaccine among Japanese Adolescents: A Cohort Study. Vaccines 2022; 10(11). Sharma A, Oda G, Holodniy M. Effectiveness of mRNA-based vaccines during the emergence of SARS-CoV-2 Omicron variant. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2022. Silva-Valencia J, Soto-Becerra P, Escobar-Agreda S, et al. Relative vaccine effectiveness of the booster dose of COVID-19 vaccine for preventing death in individuals with a primary regimen based on the BBIBP-CorV, ChAdOx1-S, or BNT162b2 vaccines during the Omicron wave in Peru: A nested case-control study using national population data. Vaccine 2022; 40(45): 6512-9. Stirrup O, Shrotri M, Adams NL, et al. Clinical effectiveness of SARS-CoV-2 booster vaccine against Omicron infection in residents and staff of Long-Term Care Facilities: a prospective cohort study (VIVALDI). 2022. Tang L, Zhang Y, Wang F, et al. Relative vaccine effectiveness against Delta and Omicron COVID-19 after homologous inactivated vaccine boosting: a retrospective cohort study. BMJ Open 2022; 12(11). Tseng HF, Ackerson BK, Bruxvoort KJ, et al. Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5. Nature Communications 2023; 14(1). Wan J, Cazer CL, Clarkberg ME, et al. Booster vaccination protection against SARSCoV-2 infections in young adults during an Omicron BA.1-predominant period: A retrospective cohort study. PLoS Medicine 2023; 20(1). | - |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/89516 | - |
dc.description.abstract | 背景:現今探討第三劑COVID-19疫苗保護效果的相關研究,仍存在相互矛盾的結果,且缺乏系統性整合的實證結論。因此,本研究旨在評估第三劑疫苗相較於兩劑基礎疫苗後所提供的額外保護效果(Vaccine effectiveness),並探討在Omicron變異株流行期間施打第三劑mRNA疫苗後之保護效果隨時間變化的情況。
方法:首先進行系統性文獻回顧(Systematic review),利用關鍵字搜尋資料庫中相關之文獻,搜尋時間至2023年3月31日,將符合篩選條件的文獻納入統合分析(Meta-analysis),並且分別估計第三劑疫苗預防Omicron變異株引起的感染、嚴重疾病,以及死亡的疫苗效果。後以統合回歸分析方法(Meta-regression),進一步探討研究間異質性影響因素,以及疫苗保護效果隨時間的變化趨勢。 結果:本研究共納入35篇文獻進行統合分析。研究結果顯示,對於預防感染Omicron變異株效果方面,在施打第三劑mRNA疫苗經過六個月後,疫苗效果從58%下降至9%;而對於預防嚴重疾病方面,施打第三劑疫苗經過五個月後,疫苗效果從80%降至55%;最後對於預防死亡方面,施打第三劑疫苗後三個月期間其疫苗效果可維持於88%。然而,疫苗保護效果在各研究間具高度異質性,分析顯示疫苗接種後的時間長短、受試者的平均年齡及第三劑疫苗廠牌的差異是影響疫苗效果的重要因素(R2 = 70.4%)。整體而言,第三劑疫苗對於預防感染的效果為中度證據品質,對於預防嚴重疾病和死亡的效果為高度證據品質。 討論及結論:在Omicron變異株流行時期,第三劑mRNA疫苗相較於兩劑基礎疫苗可產生良好的疫苗保護效果,尤其在預防嚴重疾病或死亡方面,其疫苗效果顯著。然而,針對預防感染及嚴重疾病的疫苗保護效果,在施打疫苗後的六個月內皆會隨時間逐漸下降,但整體而言,第三劑疫苗對於預防嚴重疾病仍可維持相對良好的保護效果。由於全球COVID-19持續流行,且SARS-CoV-2病毒株具高度變異性,對於公共衛生及人類健康仍造成相當程度的影響,因此,本研究建議未來仍須持續評估疫苗對於Omicron變異株的持續保護效果,以利未來防疫決策之評估。 | zh_TW |
dc.description.abstract | Background: Limited and conflicting evidence exists regarding the extra protection conferred by the third dose of mRNA vaccine against COVID-19. We aim to systematically assess the effectiveness of the third mRNA vaccine, compared with the two-dose primary series vaccination, against COVID-19 and the duration of extra protection from the third mRNA vaccine dose against the SARS-CoV-2 Omicron-variant.
Methods: We search databases for all available data up to March 31, 2023. The primary outcomes were the effectiveness of the third dose compared to the primary series vaccination in preventing SARS-CoV-2 infection, severe COVID-19 disease, and COVID-19-related death by laboratory-confirmed Omicron variant or during the Omicron predominant period. We applied meta-regression to explore sources of heterogeneity between studies. The study was registered on PROSPERO (CRD42022364568). Findings: Out of the 1,703 studies screened from the databases, 185 underwent full-text review, and 35 studies were included in the analysis. Among these, 25 studies were identified to have a moderate risk of bias, while ten studies were found to have a serious risk of bias. The effectiveness against infection was 58% (95% CI: 54% to 62%) during the first month and decreased to 9% (95% CI: -7% to 23%) by the sixth month after the third dose. The effectiveness against severe disease also decreased from 80% (95% CI: 68% to 87%) to 55% (95% CI: 49% to 60%) during a fifth-month period after the third dose. The effectiveness against COVID-19-related death remained stable at 88% (95% CI: 85% to 90%) over a three-month period after the third dose. The heterogeneity between studies can mainly be attributed to participant age, the third vaccine product used, and time elapsed after vaccination (R2 = 70.40%). Overall, moderate-certainty evidence supports the effectiveness of the third vaccine against infection, while high-certainty evidence supports the effectiveness against severe COVID-19 disease and death. Interpretation: The third mRNA vaccine dose is highly effective in conferring extra protection against Omicron variant-associated severe COVID-19 disease or death compared with primary series vaccination. Even though protection against infection drops to a negligible level after six months, the protection against severe COVID-19 disease and death persists. | en |
dc.description.provenance | Submitted by admin ntu (admin@lib.ntu.edu.tw) on 2023-09-08T16:07:50Z No. of bitstreams: 0 | en |
dc.description.provenance | Made available in DSpace on 2023-09-08T16:07:50Z (GMT). No. of bitstreams: 0 | en |
dc.description.tableofcontents | 摘要 i
背景 i 方法 i 結果 i 討論及結論 i Summary iii Background iii Methods iii Findings iii Interpretation iv Introduction 1 Methods 1 Search strategy and selection criteria 2 Data analysis 3 Results 5 Discussion 10 References 16 Figure Legends 19 Table Legends 21 Supplementary appendix 24 Supplementary Notes 26 Supplementary Note 1: MEDLINE (PubMed) Search Strategy 26 Supplementary Note 2: Embase (Elsevier) Strategy 26 Supplementary Note 3: CENTRAL (Search Manager) Search Strategy 27 Supplementary Note 4: ClinicalTrials.gov Search Strategy 27 Supplementary Note 5: WHO COVID-19 Research Database 27 Supplementary Note 6: Inclusion and Exclusion Criteria for Study Search 28 Supplementary Tables 29 Supplementary Table 1: Characteristics of Included Studies in Meta-analysis 29 Supplementary Table 2: Results of Included Studies in Meta-analysis 34 Supplementary Table 3: Risk of Bias Assessments 47 Supplementary Table 4. List of Included Studies 49 Supplementary Table 5: Study Definitions of Severe Disease in Included Studies 52 Supplementary Table 6: Summary of Findings - Certainty of Evidence for Effect Outcomes 55 Supplementary Table 7: Vaccine Effectiveness over Time since the Third Vaccination, Stratified by the Product of the Third Vaccine. 56 Supplementary Table 8: Sensitivity Analysis of Vaccine Effectiveness over Time since the Third Vaccination by Excluding Estimates with a Serious Risk of Bias. 57 Supplementary Table 9. Results of the meta-regression 58 Supplementary Figures 59 Supplementary Figure 1: Vaccine Effectiveness against SARS-CoV-2 Infection, Severe COVID-19 Disease, and COVID-19-Related Death. 59 Supplementary Figure 2: Vaccine Effectiveness Stratified by Product of the Third Vaccine. 60 Supplementary Figure 3: Vaccine Effectiveness Stratified by Mean Age of the Study Population. 61 Supplementary Figure 4: Vaccine Effectiveness Stratified by Follow-Up Period since the Third Vaccination. 62 Supplementary Figure 5. Duration of Vaccine Effectiveness After Vaccination During Omicron Variant Predominance, Stratified by the Product of the Third Vaccine. 63 Supplementary Figure 6: Sensitivity Analysis of Vaccine Effectiveness Stratified by Study Design. 64 Supplementary Figure 7: Publication Bias – Funnel Plots (Estimates of Vaccine Effectiveness throughout the Follow-up Period) 66 Supplementary Figure 8: Publication Bias – Funnel Plots (Estimates of Vaccine Effectiveness with Time Intervals since Vaccination) 67 | - |
dc.language.iso | en | - |
dc.title | Omicron 變異株流行期間第三劑 mRNA 疫苗提供的額外保護效果:系統性回顧與統合分析 | zh_TW |
dc.title | Effectiveness of the Third mRNA Vaccine Dose Against COVID-19 During the Omicron Variant Dominant Period: A Systematic Review and Meta-analysis | en |
dc.type | Thesis | - |
dc.date.schoolyear | 111-2 | - |
dc.description.degree | 碩士 | - |
dc.contributor.coadvisor | 馮嬿臻 | zh_TW |
dc.contributor.coadvisor | Yen-Chen Feng | en |
dc.contributor.oralexamcommittee | 盛望徽;劉定萍 | zh_TW |
dc.contributor.oralexamcommittee | Wang-Huei Sheng;Ding-Ping Liu | en |
dc.subject.keyword | 嚴重特殊傳染性肺炎,Omicron變異株,mRNA疫苗,疫苗保護效果,統合分析, | zh_TW |
dc.subject.keyword | COVID-19,B.1.1.529,Omicron,mRNA vaccine,Vaccine effectiveness,Meta-analysis, | en |
dc.relation.page | 67 | - |
dc.identifier.doi | 10.6342/NTU202302964 | - |
dc.rights.note | 未授權 | - |
dc.date.accepted | 2023-08-07 | - |
dc.contributor.author-college | 公共衛生學院 | - |
dc.contributor.author-dept | 流行病學與預防醫學研究所 | - |
顯示於系所單位: | 流行病學與預防醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-111-2.pdf 目前未授權公開取用 | 3.29 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。